Technical Analysis for DRUG - Bright Minds Biosciences Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 20 DMA | Bullish | -0.46% | |
| Bollinger Band Squeeze | Range Contraction | -0.46% | |
| Doji - Bullish? | Reversal | -0.46% | |
| Fell Below 20 DMA | Bearish | 0.93% | |
| Bollinger Band Squeeze | Range Contraction | 0.93% | |
| Gapped Down | Weakness | 0.93% | |
| Crossed Above 20 DMA | Bullish | -1.82% | |
| Bollinger Band Squeeze | Range Contraction | -1.82% | |
| BB Squeeze Started | Range Contraction | -1.82% | |
| Gapped Down | Weakness | -1.82% |
| Alert | Time |
|---|---|
| 20 DMA Support | 14 minutes ago |
| 10 DMA Support | 14 minutes ago |
| 60 Minute Opening Range Breakdown | 21 minutes ago |
| Down 5% | 21 minutes ago |
| Down 3% | 21 minutes ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 08/28/2023
Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.
Sector: Healthcare
Industry: Biotechnology
Keywords: Drugs Pain Organic Compounds Chemical Compounds Epilepsy Antidepressants Neurotransmitters Treatment Of Epilepsy
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Drugs Pain Organic Compounds Chemical Compounds Epilepsy Antidepressants Neurotransmitters Treatment Of Epilepsy
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 6.44 |
| 52 Week Low | 0.93 |
| Average Volume | 21,599 |
| 200-Day Moving Average | 1.68 |
| 50-Day Moving Average | 1.21 |
| 20-Day Moving Average | 1.08 |
| 10-Day Moving Average | 1.07 |
| Average True Range | 0.10 |
| RSI (14) | 45.65 |
| ADX | 25.5 |
| +DI | 13.06 |
| -DI | 18.87 |
| Chandelier Exit (Long, 3 ATRs) | 1.03 |
| Chandelier Exit (Short, 3 ATRs) | 1.22 |
| Upper Bollinger Bands | 1.17 |
| Lower Bollinger Band | 0.98 |
| Percent B (%b) | 0.54 |
| BandWidth | 17.86 |
| MACD Line | -0.05 |
| MACD Signal Line | -0.06 |
| MACD Histogram | 0.0166 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.25 | ||||
| Resistance 3 (R3) | 1.24 | 1.18 | 1.22 | ||
| Resistance 2 (R2) | 1.18 | 1.14 | 1.18 | 1.21 | |
| Resistance 1 (R1) | 1.13 | 1.11 | 1.16 | 1.14 | 1.20 |
| Pivot Point | 1.07 | 1.07 | 1.08 | 1.08 | 1.07 |
| Support 1 (S1) | 1.02 | 1.03 | 1.05 | 1.03 | 0.97 |
| Support 2 (S2) | 0.96 | 1.00 | 0.97 | 0.96 | |
| Support 3 (S3) | 0.91 | 0.96 | 0.95 | ||
| Support 4 (S4) | 0.92 |
